Those desperate to give up smoking may have breathed a sigh of relief after hearing about what Biohit says is an effective, non-addictive means to stop smoking.

Business
Tools
Typography

Biohit reveals that it received hundreds of enquiries following the publication of the results of a medical trial confirming that its Acetium lozenge is an effective, non-addictive means to quit smoking.

The Helsinki-based biotechnology firm also saw its share price jump by 7.4 per cent on the Helsinki Stock Exchange on Monday.

“We’ve received an astonishing number of contacts and enquiries – not only from Finland but in fact more from outside Finland,” Semi Korpela, the chief executive of the biotechnology firm, says to Uusi Suomi.

He believes the high interest in the results can be attributed primarily to two factors: first, because the active substance was shown to cause no side-effects and, second, because the active substance is neither addictive nor a a nicotine replacement.

“The efficacy is comparable to nicotine replacement therapy,” he said in a press release on Monday.

Kari Syrjänen, the chief medical director at Biohit, described the results of the second smoking intervention study as “a breakthrough in the development of smoking intervention methods”.

The intervention study confirmed that the lozenge is an effective tool in assisting the cessation of smoking due to its capability to absorb acetaldehyde derived from cigarette smoke in saliva, thus potentially reducing the effects of acetaldehyde in maintaining smoking addiction. Acetaldehyde has been labelled as a carcinogen by the World Health Organization (WHO).

The study was adequately powered to confirm the results of the first intervention study and their statistical significance, according to the press release from Biohit.

Korpela reveals that the biotechnology firm will now begin re-branding and re-packaging the Acetium lozenge. The product, he adds, has already been available in web-shops but has yet been marketed as a smoking cessation aid due to lack of proof of its efficacy.

After the re-packaging and other preparations have been completed, the lozenge will be made available both domestically and globally, he says. “There are still plenty of smokers in the world. There are large smoking countries in Asia, as well as in Europe and the Middle East. There’s quite a few of them. Why should we rule out anything?” says Korpela.

Aleksi Teivainen – HT
Photo: Anni Reenpää – Lehtikuva
Source: Uusi Suomi

ICP2

Finland in the world press

Partners